Cost-effective Treatment of Phimosis

Robert S. Van Howe, MD

ABSTRACT. Objective. To determine the most cost-effective treatment for phimosis.

Design. The costs of three treatment strategies for treating phimosis were evaluated using a decision-tree analysis. Three therapeutic approaches were considered: circumcision, preputial plasty (the use of plastic surgical techniques to enlarge the preputial opening without removing tissue), and topical therapy with steroids and nonsteroidal antiinflammatories. Published failure and complication rates were used to calculate the cost per case.

Outcome Measures. Cost in dollars to treat each case of phimosis.

Results. Topical steroid therapy was the most cost-effective strategy, costing between $758 and $800 per case. Preputial plasty cost between $2515 and $2580 per case. Circumcision cost between $3009 and $3241 per case.

Conclusions. The most cost-effective management for treating phimosis is to initiate topical therapy. Daily external application of the tip of the foreskin to the glans corona with betamethasone 0.05% cream for 4 to 6 weeks has been demonstrated to be very effective, resulting in a 75% savings compared with circumcision. Surgical intervention should not be considered until topical therapy has been given an adequate trial. When contemplating surgery, the lower morbidity, lower costs, and tissue preservation of preputial plasty may make it preferable. Pediatrics 1998;102(4). URL: http://www.pediatrics.org/cgi/content/full/102/4/e43; phimosis, betamethasone, preputial plasty, circumcision.

METHODS

A decision-tree analysis was performed for three initial treatment strategies: circumcision, preputial plasty, and topical steroids. The costs, complication rates, failure rates, and time missed from work (parental or personal) are listed in Table 1.

The failure rate for topical therapy was calculated by combining the results of the 10 studies published to date (Table 2). Time lost from work was based on the mean time it took after surgery for underpants to be worn comfortably. Income was assumed to be $35 000 per annum.

Although the British study by Cuckow et al documented a 20% overnight hospitalization rate after circumcision, the rate in the United States is unknown. Most of the overnight hospitalizations were secondary to anesthesia complications. Overnight hospitalization rates of 6% (the rate of reoperation for bleeding) and 20% were used for calculations. Hospitalization rates for preputial plasty were 40% of those for circumcision. The reported rates of meatal stenosis requiring meatomotomy after circumcision range from 2.8% to 11.1%. Calculations were made using meatomotomy rates of 2.8% and 8%.

For the preputial plasty group, failures were treated with circumcision. For the topical therapy, failures were treated with circumcision under the assumption that those who failed topical therapy did not respond because the underlying pathology was balanitis xerotica obliterans (BXO) based on the determination that the failure rate of topical therapy was nearly the same as the incidence of BXO in circumcision specimens (Table 3).

RESULTS

For each case of phimosis it costs between $3009 and $3241 to use circumcision as the primary treatment modality. Preputial plasty costs between $2515 and $2579 per case. Using topical therapy as the initial therapy costs between $758 and $800, a 75% savings compared with circumcision.

Topical therapy would need to exhibit a 93% failure rate to be as costly as initially relying on circumcision. A failure rate of 20% to 24% for preputial plasty would make that option as costly as circumcision. In those treated initially with topical therapy, treatment failure accounted for more of the costs than their initial therapy (Fig 1).

These calculations demonstrate that topical therapy is the most cost-efficient initial therapy for phimosis.

DISCUSSION

The definition of phimosis has never been precise and has been applied to foreskins which do not retract, have adhesions to the glans, have a “tightness,” are elongated, are “redundant,” are thickened, are inflamed, have a fibrous ring, or have a narrow orifice. In the United States physicians are encouraged to list “redundant prepuce and phimosis” as the indication for elective circumcisions on normal foreskins to receive third-party payment. Unfortunately, the term phimosis is often incorrectly

From the Department of Pediatrics, Marshfield Clinic—Lakeland Center, Minocqua, Wisconsin.

Received for publication Sep 9, 1997; accepted May 18, 1998.

Reprint requests to (R.S.V.H.) Marshfield Clinic, Lakeland Center, 9601 Townline Rd, PO Box 1390, Minocqua, WI 54548.


http://www.pediatrics.org/cgi/content/full/102/4/e43
applied to any foreskin that cannot be retracted, which includes 96% of newborns, 85% of 3 month olds, 50% of 1 year olds, and 1% of 17 year olds. The reported incidence of phimosis varies. In a population of military dependents receiving post-neonatal circumcisions, the incidence of true phimosis was between 0.2 and 0.3%. Krueger and Osborn found phimosis in 3 of 28 boys (10.7%) more than the age of 4, Herzog and Alvarez saw symptomatic phimosis in 8 of 272 intact boys (2.94%) they studied, and following a cohort of 1265 children in Christchurch, New Zealand, Fergusson et al found that 16% of noncircumcised boys aged 0 to 8 had phimosis. Whether these authors could distinguish between pathologic and physiologic phimosis through retrospective chart reconstructions is debatable. How many of these boys required intervention is likewise unknown.

Prospective studies have demonstrated phimosis to be a rare finding. Smith et al found 1 case of phimosis in 1000 boys. In 213 Japanese boys under age 2 years, only 4 (1.88%) had a “pinhole prepuce.” In France the rate is 2.6%, whereas in England, the incidence of true pathologic phimosis was calculated to be 0.9%. Øster, who examined nearly 2000 schoolchildren between the ages of 6 and 17, found that 91% of the 6- to 7-year-old age group had retractile prepuces and the incidence of spontaneously retractile foreskins increased yearly until age 17 years when only 1% of the foreskins remained nonretractile. The incidence of a completely retractile prepuce in a study of 603 Japanese boys showed a gradual increase from 0% at age 6 months to 62.9% by 11 to 15 years, while the incidence of a tight preputial ring decreased with age from 84.3% to 8.6%. One large study failed to find a case of pathologic phimosis in a boy under 5 years of age.

Without clear diagnostic criteria, confusion exists about what constitutes pathologic phimosis as distinct from a physiologic nonretractile foreskin. The majority of referrals to pediatric urologists for circumcision constitute developmentally nonretractile foreskin rather than true phimosis. When applying gentle retraction to the normal but nonretractable infant foreskin the distal part of the foreskin puckers and the narrow portion is proximal to the preputial tip. When the same gentle retraction is applied to the foreskin with true phimosis it results in a cone-shaped foreskin with a fibrotic, circular band forming the most distal and narrowest part of the prepuce.

Topical therapy has resulted in consistently favorable results (Table 2), a finding that has prompted the Australasian Association of Paediatric Surgeons to recommend circumcision only for BXO, recurrent balanoposthitis, and phimosis resistant to topical steroid cream. All three placebo-controlled studies have demonstrated topical therapy’s superiority (Table 4). The antiinflammatory and immunosuppressive effects as well as the skin thinning effects of the topical steroids may explain their effectiveness. Be tamethasone has been the most studied cream, with

| TABLE 1. Assumptions Used to Calculate the Cost-efficiency of Treating Phimosis |
|---------------------------------|---------------------------------|-------------------------------|-------------------|
| Cost per procedure              | $2000                           | $2000                         | $120              | $1000             |
| Failure rate                    | 4%                              | 18%                           |                   |                   |
| Overnight hospital stay         | 6-20%                           | 2.4-8%                        |                   |                   |
| Reoperation rate                | 3-6%                            |                               |                   |                   |
| Meatal stenosis rate            | 3.8%                            |                               | 1                 | 2                 |
| Time lost from work (days)      | 9.215                           |                               |                   |                   |
|                                |                                 |                               |                   |                   |

<p>| TABLE 2. Studies Using Topical Creams to Treat Phimosis |
|---------------------------------|---------------------------------|-------------------|</p>
<table>
<thead>
<tr>
<th>Author</th>
<th>Therapy Used</th>
<th>Number of Patients</th>
<th>Number Responding</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wright†</td>
<td>Betamethasone 0.5% three times a day</td>
<td>139</td>
<td>111</td>
<td>80</td>
</tr>
<tr>
<td>Kikiros²</td>
<td>Hydrocortisone 1% and 2%, betamethasone 0.05% twice a day four times a day</td>
<td>63</td>
<td>51</td>
<td>81</td>
</tr>
<tr>
<td>Jorgensen³</td>
<td>Clobetasol 0.05% once daily</td>
<td>54</td>
<td>38</td>
<td>70</td>
</tr>
<tr>
<td>Lange⁴</td>
<td>HCG injection, corticoid cream</td>
<td>56</td>
<td>53</td>
<td>95</td>
</tr>
<tr>
<td>Golubovic⁵</td>
<td>Betamethasone 0.05% twice a day</td>
<td>20</td>
<td>19</td>
<td>95</td>
</tr>
<tr>
<td>Müller⁶</td>
<td>Estragen 0.1% twice a day</td>
<td>30</td>
<td>27</td>
<td>90</td>
</tr>
<tr>
<td>Linghagen⁷</td>
<td>Clobetasol 0.05% once daily</td>
<td>27</td>
<td>24</td>
<td>89</td>
</tr>
<tr>
<td>Atilla⁸</td>
<td>Diclofenac three times a day</td>
<td>32</td>
<td>24</td>
<td>75</td>
</tr>
<tr>
<td>Dewan⁹</td>
<td>Hydrocortisone 1% three times a day</td>
<td>20</td>
<td>13</td>
<td>65</td>
</tr>
<tr>
<td>Ruud¹⁰</td>
<td>Potent steroid ointment†</td>
<td>41</td>
<td>35</td>
<td>85</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>482</td>
<td>395</td>
<td>82</td>
</tr>
</tbody>
</table>

* Those who did not respond to 1% hydrocortisone cream were subsequently successfully treated with 0.05% betamethasone cream.
† Twelve of the patients who initially responded relapsed.

TABLE 3. Incidence of Balanitis Xerotica Obliterans in Circumcision Specimens

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of Specimens</th>
<th>Number With Balanitis Xerotica Obliterans</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clemmensen²³</td>
<td>78</td>
<td>15</td>
</tr>
<tr>
<td>Meuli²⁴</td>
<td>100</td>
<td>10</td>
</tr>
<tr>
<td>Kristiansen²⁵</td>
<td>59</td>
<td>9</td>
</tr>
<tr>
<td>Bale²⁶</td>
<td>232</td>
<td>44</td>
</tr>
<tr>
<td>Flenje²⁷</td>
<td>140</td>
<td>6</td>
</tr>
<tr>
<td>Chalmers²⁸</td>
<td>100</td>
<td>14</td>
</tr>
<tr>
<td>Liatsikos²⁹</td>
<td>75</td>
<td>8</td>
</tr>
<tr>
<td>Total</td>
<td>709</td>
<td>98</td>
</tr>
</tbody>
</table>

2 of 4 COST-EFFECTIVE TREATMENT OF PHIMOSIS
Downloaded from by guest on April 10, 2017
external application giving similar results to mucosal application.

Although the studies using topical creams have produced dramatic results, the boys studied were often younger than 5 years old. How many of these boys merely had a normal, nonretractile prepuce is unknown. Topical therapy may have only accelerated the normal developmental process in these boys. Still, these boys would have been considered candidates for circumcision if topical therapy had not been offered. Lindhagen noted that placebo responders were 2.4 years older than placebo nonresponders, “reinforcing the opinion that this is a physiological process with increasing potential for spontaneous resolution with increasing age.”

The failure rate of topical creams (19%) is nearly identical with the rate of BXO (14%) found on histologic examination of prepuces excised from patients with phimosis. Of the boys who failed after a complete course of topical therapy, 14 had a histologic examination performed. BXO was diagnosed in 12 (86%) of them. Although topical steroids are recommended for early BXO, their use may act as a screening tool to identify those with more advanced BXO. With the development of effective topical therapy and preputial plasty, the indication for circumcision in the treatment of phimosis has been reduced to the rare cases of BXO.

Meatal stenosis requiring meatalotomy after circumcision is seen in 2.8% to 11.1% of patients. Persad et al found that after 88 circumcisions for phimosis, 7 (8%) boys developed meatal stenosis, whereas none of the 91 boys who underwent preputial plasty did ($P < .01$). Traumatic meatitis of the unprotected post-circumcision urethral meatus and/or meatal ischemia after damage to the frenular artery at circumcision have been cited as possible etiologic factors.

Of two similar groups of 50 boys, one underwent circumcision and the other underwent preputial plasty in a recent British study. Of the boys who underwent circumcision, 20% required an overnight stay, 14% had anesthetic complications, and 6% required reoperation because of bleeding. Only 8% of patients had an overnight stay after preputial plasty. None of these patients required reoperation and no bleeding problems were noted. Parental assessment of both operations showed that morbidity was significantly less and of shorter duration for the preputial plasty group. Two patients in the preputial plasty group (4%) had recurrent narrowing of the foreskin caused by scarring and contraction of the incision. The acceptance of preputial plasty as an alternative to circumcision may not occur immediately, despite reductions in cost, morbidity, and the amount of tissue excised, because most surgeons will need to be convinced of the need for change.

Several noneconomic factors deserve consideration. The ridged band at the tip of the prepuce may be the most neurologically complex portion of the penis. Topical therapy and preputial plasty both spare this highly erogenous tissue. Likewise, severe emotional problems have been documented after circumcision in young boys. The vast majority of males with a prepuce are not eager to part with it, and these newly developed therapies provide reasonable alternatives.

Lindhagen states, “contrary to epidemiological

---

### TABLE 4. Placebo-controlled Studies of Topical Therapy for Phimosis Response to Therapy

<table>
<thead>
<tr>
<th>Study</th>
<th>Medication</th>
<th>Placebo</th>
<th>Odds Ratio</th>
<th>95% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Atilla 8</td>
<td>24</td>
<td>8</td>
<td>3</td>
<td>17</td>
</tr>
<tr>
<td>Lindhagen</td>
<td>10</td>
<td>3</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Golubovic</td>
<td>19</td>
<td>1</td>
<td>4</td>
<td>16</td>
</tr>
<tr>
<td>Total</td>
<td>53</td>
<td>12</td>
<td>14</td>
<td>40</td>
</tr>
</tbody>
</table>

---

Fig 1. Costs of treating phimosis.
data that showed spontaneous resolution of most cases of phimosis, circumcision has become the first line of treatment for these patients. The argument that circumcision is a minor surgical procedure without complications is not only erroneous, but also irrelevant. It is ethically as well as economically questionable to operate on a child to treat a physiological process."

ACKNOWLEDGMENT
I thank Christopher J. Cold, MD, for his invaluable assistance in explaining the pathology of BXO.

REFERENCES
3. Jørgensen ET, Svensson A. The treatment of phimosis in boys, with a potent topical steroid (clobetasol propionate 0.05%) cream. Acta Derm Venereol (Stockh). 1993;73:55–56
36. Otis FN. Reflex hemiplegia and paralysis of the bladder from congenital phimosis in children. Am J Obstet. 1874;479
37. Reimbursement adviser: how to get reimbursed for circumcision. ORG Management 1993(Oct);25
52. Australasian Association of Paediatric Surgeons. Guidelines for Circumcision. Sydney, Queensland, Australia: Australasian Association of Paediatric Surgeons; April 1996
Cost-effective Treatment of Phimosis
Robert S. Van Howe
Pediatrics 1998;102;e43

Updated Information & Services
including high resolution figures, can be found at:
/content/102/4/e43.full.html

References
This article cites 49 articles, 7 of which can be accessed free at:
/content/102/4/e43.full.html#ref-list-1

Citations
This article has been cited by 1 HighWire-hosted articles:
/content/102/4/e43.full.html#related-urls

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Fetus/Newborn Infant
/cgi/collection/fetus:newborn_infant_sub
Circumcision
/cgi/collection/circumcision_sub
Urology
/cgi/collection/urology_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
/site/misc/reprints.xhtml
Cost-effective Treatment of Phimosis
Robert S. Van Howe
Pediatrics 1998;102:e43

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/102/4/e43.full.html